KalVista Pharmaceuticals, Inc. Stock price

Equities

KALV

US4834971032

Pharmaceuticals

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
11.86 USD +7.14% Intraday chart for KalVista Pharmaceuticals, Inc. -2.39% -3.18%
Sales 2024 * - Sales 2025 * 16.49M Capitalization 500M
Net income 2024 * -114M Net income 2025 * -111M EV / Sales 2024 * -
Net cash position 2024 * 260M Net cash position 2025 * 139M EV / Sales 2025 * 21.9 x
P/E ratio 2024 *
-3.9 x
P/E ratio 2025 *
-4.85 x
Employees 118
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.86%
More Fundamentals * Assessed data
Dynamic Chart
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas CI
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas CI
KalVista Pharmaceuticals Names Benjamin Palleiko as CEO MT
KalVista Pharmaceuticals, Inc. Announces Board Changes CI
KalVista Pharmaceuticals, Inc. Announces Chief Executive Officer Changes CI
KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency CI
Kalvista Pharmaceuticals Insider Sold Shares Worth $613,205, According to a Recent SEC Filing MT
Kalvista Pharmaceuticals Insider Sold Shares Worth $598,661, According to a Recent SEC Filing MT
Kalvista Pharmaceuticals Insider Sold Shares Worth $422,827, According to a Recent SEC Filing MT
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting CI
HC Wainwright Adjusts Price Target on KalVista Pharmaceuticals to $24 From $16, Maintains Buy Rating MT
KalVista Pharmaceuticals' Phase 3 Trial of Sebetralstat to Treat Hereditary Angioedema Meets All Endpoints; Shares Rise MT
Transcript : KalVista Pharmaceuticals, Inc. - Special Call
KalVista meets main goals in late-stage trial for genetic disease RE
More news

Latest transcript on KalVista Pharmaceuticals, Inc.

1 day+7.14%
1 week-2.39%
Current month-13.11%
1 month-11.43%
3 months-1.82%
6 months+22.77%
Current year-3.18%
More quotes
1 week
10.70
Extreme 10.7
12.46
1 month
10.70
Extreme 10.7
14.62
Current year
10.70
Extreme 10.7
16.88
1 year
7.21
Extreme 7.21
16.88
3 years
4.12
Extreme 4.12
30.70
5 years
4.12
Extreme 4.12
45.00
10 years
0.00
Extreme 0
45.00
More quotes
Managers TitleAgeSince
Founder 64 04-03-25
Chief Executive Officer 58 16-07-31
Chief Tech/Sci/R&D Officer 51 21-05-02
Members of the board TitleAgeSince
Chairman 65 19-01-31
Chief Executive Officer 58 16-07-31
Director/Board Member 51 15-12-31
More insiders
Date Price Change Volume
24-03-28 11.86 +7.14% 2,152,861
24-03-27 11.07 -0.36% 266,046
24-03-26 11.11 -0.18% 520,289
24-03-25 11.13 -6.08% 514,138
24-03-22 11.85 -2.47% 270,724

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). The Company is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial. The Company is also conducting preclinical development on oral Factor XIIa (Factor XIIa) inhibitor program, which is advancing to provide the next generation of HAE therapeutics. It is also focused on development of oral plasma kallikrein inhibitors for HAE and Factor XIIa inhibitors for HAE and other indications. Plasma kallikrein is a serine protease enzyme that is a key mediator of inflammation and edema.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
11.86 USD
Average target price
31.6 USD
Spread / Average Target
+166.44%
Consensus
  1. Stock
  2. Equities
  3. Stock KalVista Pharmaceuticals, Inc. - Nasdaq